UMMID Phase-II Launched for Rare Genetic Disorders
Why in the news
The Science and Technology Minister of State (Independent Charge) opened the second stage of a national drive for diagnosing inherited diseases.
Key facts
- Programme: Unique Methods of Management and Treatment of Inherited Disorders (UMMID), Phase-II.
- Launched by: Dr Jitendra Singh, MoS (IC), Ministry of Science and Technology.
- Implementer: Department of Biotechnology (DBT).
- Phase-I: 23 September 2019, billed as India’s first comprehensive national initiative for molecular diagnostics of rare diseases.
| Phase-II component | Role |
|---|---|
| 25 new NIDAN Kendras (13 states + 1 UT) | Advanced genetic diagnosis and counselling |
| 3 training centres: Hyderabad, Bengaluru, Chandigarh | Capacity-building for doctors and geneticists |
| Community outreach | Screening and awareness in underserved areas |
| UMMID Dashboard | Nationwide digital monitoring |
Background
- NIDAN Kendras (National Inherited Diseases Administration Kendras) provide molecular tests, family counselling and clinical support.
- Rare Genetic Disorders affect a small share of people; WHO is cited as using under 1 in 2,000. Many are single-gene conditions such as thalassemia, sickle cell anaemia, haemophilia and Duchenne muscular dystrophy.
- National Policy for Rare Diseases (2021) offers a framework for diagnosis, treatment and financial support.
- DBT was set up in 1986 under the Ministry of Science and Technology and also backs the Genome India Project, BIRAC and the National Biopharma Mission.
Significance
- An estimated 70-100 million Indians live with rare genetic disorders.
- Late diagnosis is common because specialists and tests are scarce; molecular testing allows early and accurate detection.
- Local outreach improves fairness of access.
Exam angle
- Full form of UMMID and NIDAN; implementing agency DBT, not ICMR.
- Numbers: 25 centres, 13 states + 1 UT, 3 training centres, 23 September 2019.